Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Khodr, Tello
RightHeartIII, NCT03362047 / 2015-002835-17: (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)	Completed	2	7	Europe	Riciguat Group, Macitentan Group	University of Giessen, Philipps University Marburg	Pulmonary Arterial Hypertension (PAH)	07/24	08/24
Dumitrescu, Daniel
RightHeartIII, NCT03362047 / 2015-002835-17: (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)	Completed	2	7	Europe	Riciguat Group, Macitentan Group	University of Giessen, Philipps University Marburg	Pulmonary Arterial Hypertension (PAH)	07/24	08/24
REDUCELAPHFIII, NCT03191656: REDUCE LAP-HF III Corvia Protocol 1701	Recruiting	N/A	500	Europe	IASD Implant	Corvia Medical	Heart Failure	07/26	07/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Khodr, Tello
RightHeartIII, NCT03362047 / 2015-002835-17: (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)	Completed	2	7	Europe	Riciguat Group, Macitentan Group	University of Giessen, Philipps University Marburg	Pulmonary Arterial Hypertension (PAH)	07/24	08/24
Dumitrescu, Daniel
RightHeartIII, NCT03362047 / 2015-002835-17: (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)	Completed	2	7	Europe	Riciguat Group, Macitentan Group	University of Giessen, Philipps University Marburg	Pulmonary Arterial Hypertension (PAH)	07/24	08/24
REDUCELAPHFIII, NCT03191656: REDUCE LAP-HF III Corvia Protocol 1701	Recruiting	N/A	500	Europe	IASD Implant	Corvia Medical	Heart Failure	07/26	07/28